Quick Answer
Cardiff Oncology, Inc. reported Cash And Cash Equivalents At Carrying Value of $17.47 million for the year ending 2025.
- Cardiff Oncology, Inc. showed a decrease of -66.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Cardiff Oncology, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 29,660.0%.
- Historical annual values: Fiscal year 2025: $17.47 million | Fiscal year 2024: $51.47 million | Fiscal year 2023: $21.66 million | Fiscal year 2022: $16.35 million | Fiscal year 2021: $11.94 million | Fiscal year 2020: $130.98 million | Fiscal year 2019: $10.20 million | Fiscal year 2018: $11.45 million | Fiscal year 2017: $8.23 million | Fiscal year 2016: $13.92 million | Fiscal year 2015: $67.49 million | Fiscal year 2014: $27.29 million | Fiscal year 2013: $25.84 million | Fiscal year 2012: $10.82 million | Fiscal year 2011: $700.4 thousand | Fiscal year 2010: $58.7 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: